ERIS Lifesciences Q1 FY27 Earnings Call: Targets 14% Domestic Growth, Sunday Brand Captures 20% Market Share

ERIS Lifesciences Ltd held its Q1 FY27 earnings call on July 29, 2026. Here's a quick read of what management said — performance, strategy, and the outlook ahead.

Headline Financials in a Mixed Quarter

• Consolidated revenue grew 13% YoY — in Q1 FY26-27, with domestic formulations revenue up 14% YoY and 7 of 10 therapies delivering double-digit growth.
• EBITDA margin of 35% — reported for Q1 FY26-27, with EBITDA growing 7% YoY; the margin reflects the increasing weight of lower-margin biologics and insulins in the mix.
• Profit after tax expanded 14.5% YoY — in Q1 FY26-27, with EPS of Rs.10.3; the effective tax rate declined to 20% from 22.5% in Q1 FY25-26.
• Operating cash flow at 77% of EBITDA — for Q1 FY26-27, with management expecting this ratio to sustain for the full FY26-27; CAPEX stood at Rs.88 crores in the quarter.
• Gross margin declined to 74% — in Q1 FY26-27 from the 76-77% band in FY25-26, driven by product mix shift toward insulins (30-31% gross margin) and biologics (as low as 20% gross margin).

Cardiac Lags; Women's Health, Derma and CNS Outperform

• Cardiac segment underperformed in Q1 FY26-27 — attributed to the hypertension portfolio; management expects recovery to market growth within two quarters, by Q3 FY26-27, supported by the Isaxerone (non-steroidal MRA) launch in August 2026, targeting to bridge the segment growth gap from 11% to 15% in FY26-27.
• DVF segment delivered 14% revenue growth — in Q1 FY26-27, with the insulin franchise continuing to gain market share and the semaglutide brand Sunday contributing positively.
• Women's Health and Derma are already outperforming the market — management confirmed both segments are delivering above-market growth in Q1 FY26-27, with no specific numeric targets disclosed.
• CNS segment expected to deliver market-beating growth — for the remainder of FY26-27 and beyond, supported by a recently launched product generating strong returns, per management commentary.
• Internal OID growth of ~6% in Q1 FY26-27 — below the market growth of 11%, due to a product ban anomaly expected to resolve in August 2026; management aims to bridge the gap through new launches and renewed focus in FY26-27.
• Vitamin segment growth in Q1 FY26-27 — not attributed to a rub-off effect from GLP-1 uptake; management has no structural explanation, only a hunch that stocking may have been liberalized.

Sunday Brand Gains Traction Amid Slower Market Uptake

• Semaglutide brand Sunday achieved 20% market share by volume and 14% by value — in its first full quarter after launch (Q1 FY26-27), with a monthly run rate of Rs.4 crores; management expects upward movement in Q2 FY27.
• Patient resistance emerging at the clinic level — in Q1 FY26-27, partly due to social media chatter, but early clinical outcomes among patients on the drug for 2-3 months show HbA1c reductions to 5.3 and 5.2, liver fat reduction, and LDL correction.
• 70% of prescriptions from endocrinologists/diabetologists — which management views as a positive sign for future flow into the broader prescriber base; the immediate challenge is increasing the prescriber count, not pricing.
• Obesity SKU (Vigovy GX) to launch in August 2026 — in Q2 FY27, expected to add incremental revenue; no price reduction is planned until the prescriber base reaches 4,000-5,000 with a P/B/D of 15-18.
• Supply issues for semaglutide are now resolved — the slower-than-expected market takeoff provided the industry 3-4 months to build backend integration; the company's own facility received its license recently.
• Market uptake has been slower than company expectations — management noted that the recent increase in IPM growth rates may be due to inventory build-up at retail following the GST reduction, rather than a fundamental change in prescription or OPD data.

Gross Margin Compression; Bhopal Ramp-Up Offers Recovery Path

• Domestic EBITDA margin declined to ~35% in Q1 FY26-27 — from ~37% in FY25-26, driven entirely by a 300 bps gross margin contraction; management attributed this to product mix shift, not OAD (oral anti-diabetic) sales weakness.
• Q2 FY26-27 gross margins expected similar to Q1 — with improvement in Q3 FY26-27 and a return to normal levels by Q4 FY26-27, as the Bhopal facility ramps up production and yields improve.
• Bhopal facility to commercialize in August 2026 — with full operational ramp-up expected by the end of Q3 FY26-27; management expects this to improve gross margins, as the unit startup occurs in Q2 FY26-27.
• Swiss Parental remediation compressing EBITDA margin by a couple of 100 bps — in FY26-27, with growth guided at neutral to low single-digit vs FY25-26; improvement expected in Q4 FY26-27, with clearer guidance by end of Q2 FY26-27.
• Raw material cost impact on domestic formulations is a minor blip — higher solvent prices contributed to gross margin contraction but not significantly; the international business faced more disruption from shipping and receiving delays.
• CAPEX of Rs.88 crores in Q1 FY26-27 — with operating cash flow at 77% of EBITDA; management expects the cash flow-to-EBITDA ratio to sustain for the full FY26-27.

Insulin Franchise Gains Share; Analogs and Biologics in the Pipeline

• Insulin franchise continues to gain market share — in Q1 FY26-27, with headroom from existing products (RHI, Glargine) and a pipeline of insulin analogs; the biologics business YTM run rate is high at Rs.15-16 lakh.
• Insulin analogs: three engineering batches completed — regulatory filing for the next phase expected in Q2 FY26-27; the S-part launch is targeted within calendar year 2026 (FY26-27), while other launches are pushed to FY27-28.
• Eris analogs guided for Q3 FY26-27 with significant caution — management noted prior "hits and misses" and expressed skepticism about committing to a precise date, though the target remains Q3 FY26-27.
• Biologics gross margins as low as 20% — compared to insulins at 30-31%; the product mix shift toward these segments is the primary driver of the 74% consolidated gross margin in Q1 FY26-27, down from 76-77% in FY25-26.
• International base business largely uninterrupted — with no EU contribution in Q1 FY26-27; CAPA actions are on track, and sites are expected to be audit-ready by December CY2026.
• Swiss Parental growth softer than anticipated — due to facility remediation; management expects no major revenue impact for FY26-27, but EBITDA margin may compress by a couple of 100 bps, with improvement in Q4 FY26-27.

Targeting 14% Domestic Growth; Manufacturing Investment Prioritised

• Eris targets 14% domestic growth in FY26-27 — 300 bps ahead of the expected market growth of 11%; full-year revenue guidance maintained, with more details to be shared in Q2 FY27.
• Exports guided flattish to low single-digit growth in FY27 — with a margin impact of 200-300 bps; international base business is largely uninterrupted, but no EU contribution is expected in the near term.
• No current plans for acquisitions — after integrating Biocon's insulin business, the priority for FY26-27 and early FY27-28 is investing in facilities and technology on the manufacturing side; management is "largely staying away from acquisitions for the foreseeable future."
• Management believes Eris has "turned the corner" — after building backend capabilities in biologics, insulins, and oncology over the past few years; if execution succeeds, the company could structurally reach a "top tier of growth," with one significant portfolio growing ahead of the market and the routine business growing at a double-digit rate.
• Aspirational 2-3 year targets cited — with a structural portfolio shift as the enabler to reach a "top tier of growth," but management noted it "has to play out"; no firm numeric guidance was given for doubling revenue in 3-5 years, and management referred to historical performance without committing absent inorganic activities.
• MR headcount at 4,000 — with incremental hiring planned for H2 FY26-27 but described as not material; the company is focused on improving productivity from the existing field force.
• Last year (FY25-26) the company was stuck at ~11-11.5% EBITDA margin — management acknowledged the progress needed to reach the aspirational growth tier, with the domestic EBITDA margin at ~35% in Q1 FY26-27, down from ~37% in FY25-26.